PRECIGEN, INC. Deferred Tax Assets, Investment in Subsidiaries
PRECIGEN, INC. (PGEN) had Deferred Tax Assets, Investment in Subsidiaries of $0 as of 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsInvestmentInSubsidiaries · last filed 2021-03-01
- 2020-12-31: Deferred Tax Assets, Investment in Subsidiaries $0.00.
- 2019-12-31: Deferred Tax Assets, Investment in Subsidiaries $8.59M.
- 2018-12-31: Deferred Tax Assets, Investment in Subsidiaries $0.00.
| Period end | Deferred Tax Assets, Investment in Subsidiaries |
|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-03-01 |
| 2019-12-31 | $8.59M 10-K · filed 2021-03-01 |
| 2018-12-31 | $0.00 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |